Pregabalin and gabapentin become controlled drugs to cut deaths from misuse

@article{Mayor2018PregabalinAG,
  title={Pregabalin and gabapentin become controlled drugs to cut deaths from misuse},
  author={Susan Mayor},
  journal={British Medical Journal},
  year={2018},
  volume={363}
}
  • S. Mayor
  • Published 2018
  • Medicine
  • British Medical Journal
Pregabalin and gabapentin will be reclassified as class C controlled substances in the UK from next April to reduce the growing number of deaths associated with their misuse, the government has said.1 Victoria Atkins, parliamentary under secretary for crime, safeguarding, and vulnerability, said, “Any death related to the misuse of drugs is a tragedy. We accepted expert advice and will now change the law to help prevent misuse of pregabalin and … 
Need for international classification of gabapentin as a controlled substance
TLDR
Mayor notes that the United Kingdom will reclassify pregabalin and gabapentin—that is, gapapentinoids—as class C controlled substances in April 2019, which will require a physical prescriber signature for each prescription. Expand
Pregabalin and gabapentin: what impact will reclassification have on doctors and patients?
TLDR
After representation from community pharmacy groups4 it has been decided that pregabalin and gabapentin will be exempt from safe custody regulations, meaning that they will not be required to be kept in controlled drug cabinets. Expand
Misuse and Mortality Related to Gabapentin and Pregabalin are Being Under-Estimated: A Two-Year Post-Mortem Population Study.
TLDR
GBP and PGL are being significantly under reported in fatalities, both drugs are extensively used with opioids and the prevalence of PGL in heroin users is highly significant. Expand
Gabapentinoids associated with increased risk of suicidal behaviour
TLDR
Researchers looked at the associations between gabapentinoids and adverse outcomes related to coordination disturbances, mental health, and criminality, and found the risks were strongest among 15 to 24 year olds. Expand
Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland.
TLDR
Gabapentinoid prescribing has increased dramatically since 2006, as have dangerous co-prescribing and death (including DRDs). Expand
Often Off-label: Questionable Gabapentinoid Use Noted at Hospital Admission Warrants Deprescribing.
TLDR
There is an opportunity to deprescribe gabapentinoids on the basis of few gabAPentinoid users having a documented indication and the recent research showing potentials for harm and abuse, according to Gingras et al. Expand
Therapeutic drug monitoring of gabapentin in various indications
TLDR
The aim of the study was to investigate the use and pharmacokinetic variability of gabapentin in epilepsy and non‐epilepsy indications and to further evaluate the use of TDM in patients with restless legs syndrome (RLS). Expand
Pregabalin and gabapentin associated with depression and suicidal ideation
  • M. King
  • Medicine
  • British Medical Journal
  • 2018
Abuse of pregabalin and gabapentin for their euphoric effects may only be part of the story.1 Pregabalin …
The Effectiveness of Non-Benzodiazepine, Non-Barbiturate Medications for Alcohol Withdrawal Syndrome: A Rapid Systematic Review.
TLDR
Gabapentin could be an alternative although like benzodiazepines is not without risk when used in the community, and future RCTs must aim to improve upon the quality of evidence. Expand
Patterns of pregabalin initiation and discontinuation after its subsidy in Australia
Following the 2013 public subsidy of pregabalin in Australia for neuropathic pain not responding to other medicines, use and misuse increased substantially. We used pharmaceutical dispensing claimsExpand
...
1
2
3
...

References

UK government to reclassify pregabalin and gabapentin after rise in deaths
The UK government is to reclassify the prescription drug pregabalin as a class C controlled substance, after experts issued safety warnings following an increase in deaths linked to its use. A HomeExpand